In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

The management of chronic cough is described in evidence-based guidelines that appear to be effective for diagnosing and treating the many underlying causes of chronic cough. However, the ...

Tezepelumab is an epithelial cytokine blocker used to treat severe asthma; its efficacy and safety in patients with chronic rhinosinusitis with nasal polyps have been unclear. New research ...

For patients with ER-positive, HER2-negative breast cancer, current therapies have several disadvantages, including limited efficacy in patients with ESR1 mutations. New research findings are ...

Automated insulin delivery (AID) systems have been shown to be beneficial for patients with type 1 diabetes, but data are needed from randomized, controlled trials regarding their role in the ...

Even as hospitals in Gaza were turned into battlefields, some Palestinian–Israeli health care programs bridged the deep divides and continued to build trust between the populations in conflict.

For patients with IgG4-related disease, there are no approved therapies. New research findings on the efficacy and safety of inebilizumab ― a monoclonal antibody that targets and depletes CD19 ...

A 27-year-old man presented with a 6-month history of an itchy rash. Confluent, hyperpigmented plaques across the torso and upper arms and axillary and inguinal lymphadenopathy were noted on ...

When his mother is diagnosed with what medicine calls “heart failure,” an epidemiologist identifies harmful flaws in both the term and communication with patients and families.

To the Editor: In the final, 10-year outcomes of the CheckMate 067 trial reported by Wolchok et al. (Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented ...